In Australia, is Addyi (Flibanserin) available or what is available?
Australia Leads the Way in Androgen Treatment for Women with HSDD
While the US-approved drug flibanserin offers limited benefit for Hypoactive Sexual Desire Disorder (HSDD), it’s not approved in Australia—and comes with notable side effects.
Instead, Australia is the only country in the world to approve a regulated androgen hormone treatment specifically for postmenopausal women with HSDD. This topical therapy restores androgen levels to those typical of premenopausal women and is backed by decades of Australian-led research.
This marks a major step forward in addressing gender equity in sexual health care.
Latest News
World Menopause and Work Day
September 7 is the World Menopause and Work Day. EMAS launched the day in 2021 following the publication of its Global consensus recommendations on menopause… Continue Reading →
The Female Sexual Response—It’s Not Just About Spontaneous Desire
The Female Sexual Response—It’s Not Just About Spontaneous Desire Sexual desire in women often follows a different path than we expect. According to the Basson… Continue Reading →
In Australia, is Addyi (Flibanserin) available or what is available?
Australia Leads the Way in Androgen Treatment for Women with HSDD While the US-approved drug flibanserin offers limited benefit for Hypoactive Sexual Desire Disorder (HSDD), it’s… Continue Reading →